Kodiak Sciences (NASDAQ:KOD) Now Covered by Capital One Financial

Capital One Financial started coverage on shares of Kodiak Sciences (NASDAQ:KODGet Rating) in a research note issued to investors on Tuesday, The Fly reports. The brokerage set an “overweight” rating and a $24.00 price target on the stock. Capital One Financial‘s price target would indicate a potential upside of 212.50% from the stock’s previous close.

A number of other brokerages have also weighed in on KOD. Citigroup dropped their price objective on shares of Kodiak Sciences from $8.00 to $6.00 in a report on Thursday, November 10th. Morgan Stanley dropped their price objective on shares of Kodiak Sciences from $12.00 to $9.00 and set an “equal weight” rating on the stock in a report on Monday. The Goldman Sachs Group dropped their price objective on shares of Kodiak Sciences from $9.00 to $8.00 and set a “neutral” rating on the stock in a report on Thursday, November 10th. Truist Financial upped their price target on shares of Kodiak Sciences from $10.00 to $15.00 and gave the company a “buy” rating in a report on Tuesday, August 9th. Finally, Chardan Capital lowered their price target on shares of Kodiak Sciences from $19.00 to $18.00 and set a “buy” rating on the stock in a report on Wednesday, August 10th. Two equities research analysts have rated the stock with a sell rating, three have issued a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $25.11.

Kodiak Sciences Trading Down 4.1 %

Shares of KOD stock opened at $7.68 on Tuesday. The business’s fifty day simple moving average is $7.78 and its 200-day simple moving average is $8.33. The company has a market cap of $401.73 million, a PE ratio of -1.12 and a beta of 1.81. Kodiak Sciences has a 12-month low of $4.90 and a 12-month high of $21.70.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of KOD. Nisa Investment Advisors LLC raised its position in shares of Kodiak Sciences by 2,392.7% during the 1st quarter. Nisa Investment Advisors LLC now owns 30,785 shares of the company’s stock worth $238,000 after purchasing an additional 29,550 shares during the last quarter. SG Americas Securities LLC raised its holdings in Kodiak Sciences by 91.7% in the 1st quarter. SG Americas Securities LLC now owns 34,728 shares of the company’s stock valued at $268,000 after acquiring an additional 16,616 shares during the last quarter. State of New Jersey Common Pension Fund D raised its holdings in Kodiak Sciences by 76.3% in the 1st quarter. State of New Jersey Common Pension Fund D now owns 50,192 shares of the company’s stock valued at $387,000 after acquiring an additional 21,724 shares during the last quarter. Monaco Asset Management SAM acquired a new stake in Kodiak Sciences in the 1st quarter valued at about $581,000. Finally, Qube Research & Technologies Ltd acquired a new stake in Kodiak Sciences in the 1st quarter valued at about $431,000. Institutional investors and hedge funds own 78.37% of the company’s stock.

Kodiak Sciences Company Profile

(Get Rating)

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.

Further Reading

The Fly logo

Analyst Recommendations for Kodiak Sciences (NASDAQ:KOD)

Receive News & Ratings for Kodiak Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kodiak Sciences and related companies with MarketBeat.com's FREE daily email newsletter.